Recursion Pharmaceuticals announced it has hired Dr. Chand Sishta as the senior director of regulatory affairs. Chand joins the company after 25 years in regulatory sciences, most recently at Bristol-Myers Squibb as the Director of Global Regulatory Sciences for Mature Products, where he led regulatory activities in many countries and where he was the FDA liaison in multiple therapeutic areas.
Recursion Pharmaceuticals is preparing to take their first discoveries through Investigational New Drug (IND) approval and the start of clinical trials. Recursion advances towards its ultimate goal of 100 new treatments by 2025, new modes of thinking about all phases of discovery and development are needed. Sishta's drug development experience across the domains of quality assurance (QA); chemistry, manufacturing and controls (CMC); and regulatory affairs will be integral to the company in navigating this process.
"I'm really excited to join this fast-growing company focused on new treatments for rare diseases, and beyond," said Sishta. "And to provide inventive regulatory affairs solutions in a fast-paced start-up environment."
Recursion Pharmaceutical's discovery platform joins technology to repurpose drugs and shelved assets, as well as discover new chemical entities, mapping them to rare conditions, diseases of inflammation and immuno-oncology.